Peter Salgo, MD, Columbia University Irving Medical Center

Experts address barriers to overcome regarding naloxone prescribing, dispensing, and utilization that they have seen in the community.

Multidisciplinary expert panel share perspectives on stigmatization and normalization of the conversation about naloxone between clinicians and patients.

Henry Nasrallah, MD, recalls the history behind long-acting injectables in patients with schizophrenia.

A panel of experts in psychiatric treatment review the burden schizophrenia has on the health care system.

Joshua Lynch, DO, EMT-P, FAAEM, FACEP, shares ways to improve naloxone accessibility, and Theresa Mallick-Searle, MS, RN-BC, ANP-BC, discusses stigmatization.

Experts weigh in on protocols, policies, and programs that influence patient safety and address when a conversation should ensue with patients about naloxone.

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, explain how to increase patient adherence to treatment and address the stigma associated with schizophrenia even in the family of the patient.

Henry Nasrallah, MD, examines schizophrenia relapse, specifically how to diagnose and prevent it before further damage has transpired in the patient’s brain.  

Theresa Mallick-Searle, MS, RN-BC, ANP-BC, shares her perspective on the new labeling requirements put forth by the FDA for opioids in regards to naloxone.

Joshua Lynch, DO, EMT-P, FAAEM, FACEP, highlight risks he has seen in the community for unintended users as well as patients for accidental opioid overdose.

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, discuss the challenges and unmet needs psychiatrists and their teams face when treating patients with schizophrenia and their multiple comorbidities.

Joe Avelino, RN, BSN, MHSA, CPHQ, and Henry Nasrallah, MD, review schizophrenia and the needs of these patients.

Jeffrey Bratberg, PharmD, FAPhA, leads discussion tackling common opioid-related misconceptions as well as unintended consequences of the opioid crisis.

Jeremy Adler, DMSc, PA-C, DFAAPA, leads discussion on elements that negatively impacts the quality of care for patients requiring pain management.

Experts discuss opioid crisis complexities, such as the able to manage pain appropriately and the impact of social and structural determinates of health.